Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Tan Wan Ling
Dr Chia Puey Ling
Published by HT Digital Content Services with permission from Health Daily Digest....